New injection shows promise for severe hand eczema

NCT ID NCT05958407

Completed Disease control Sponsor: LEO Pharma Source: ClinicalTrials.gov ↗

Summary

This completed Phase 3 trial tested whether tralokinumab injections every two weeks could safely and effectively treat moderate-to-severe atopic hand eczema. The study involved 235 adults whose hand eczema did not improve enough with standard creams and who also had eczema elsewhere on their body. For the first 16 weeks, participants received either the real drug or a placebo injection, then all received the real drug for another 16 weeks to measure skin clearance, itch and pain reduction, and quality of life improvements.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

LEO Investigational Site

Bretzenheim, 55128, Germany
LEO Pharma Investigational Site

Birmingham, Alabama, 35209, United States
LEO Pharma Investigational Site

Fort Smith, Arkansas, 72916, United States
LEO Pharma Investigational Site

Fountain Valley, California, 92708, United States
LEO Pharma Investigational Site

Los Angeles, California, 90025, United States
LEO Pharma Investigational Site

Sacramento, California, 95816, United States
LEO Pharma Investigational Site

Farmington, Connecticut, 06032, United States
LEO Pharma Investigational Site

Hialeah, Florida, 33012, United States
LEO Pharma Investigational Site

Plainfield, Indiana, 46168, United States
LEO Pharma Investigational Site

Louisville, Kentucky, 40217, United States
LEO Pharma Investigational Site

New Orleans, Louisiana, 70115, United States
LEO Pharma Investigational Site

Bangor, Maine, 04401, United States
LEO Pharma Investigational Site

Caledonia, Michigan, 49316, United States
LEO Pharma Investigational Site

Detroit, Michigan, 48202, United States
LEO Pharma Investigational Site

Portsmouth, New Hampshire, 03801, United States
LEO Pharma Investigational Site

Cortland, New York, 13045, United States
LEO Pharma Investigational Site

New York, New York, 10075, United States
LEO Pharma Investigational Site

Portland, Oregon, 97201, United States
LEO Pharma Investigational Site

Portland, Oregon, 97210, United States
LEO Pharma Investigational Site

Nashville, Tennessee, 37211, United States
LEO Pharma Investigational Site

Dallas, Texas, 75225, United States
LEO Pharma Investigational Site

Frisco, Texas, 75034, United States
LEO Pharma Investigational Site

San Antonio, Texas, 78213, United States
LEO Pharma Investigational Site

Webster, Texas, 77598, United States
LEO Pharma Investigational Site

Brussels, 1200, Belgium
LEO Pharma Investigational Site

Edegem, 2650, Belgium
LEO Pharma Investigational Site

Calgary, Alberta, T3E 0B2, Canada
LEO Pharma Investigational Site

Edmonton, Alberta, T5J 3S9, Canada
LEO Pharma Investigational Site

Edmonton, Alberta, T6X 0N9, Canada
LEO Pharma Investigational Site

Red Deer, Alberta, T4P 1K4, Canada
LEO Pharma Investigational Site

Surrey, British Columbia, V3R 6A7, Canada
LEO Pharma Investigational Site

Fredericton, New Brunswick, E3B 1G9, Canada
LEO Pharma Investigational Site

Hamilton, Ontario, L8L 3C3, Canada
LEO Pharma Investigational Site

Richmond Hill, Ontario, L4B 1A5, Canada
LEO Pharma Investigational Site

Toronto, Ontario, M2N 3A6, Canada
LEO Pharma Investigational Site

Windsor, Ontario, N8T 1E6, Canada
LEO Pharma Investigational Site

Saint-Jérôme, Quebec, J7Z 7E2, Canada
LEO Pharma Investigational Site

Québec, G1V 4X7, Canada
LEO Pharma Investigational Site

Québec, G1W 4R4, Canada
LEO Pharma Investigational Site

Nantes, 44093, France
LEO Pharma Investigational Site

Pierre-Bénite, 69495, France
LEO Pharma Investigational Site

Rouen, 76031, France
LEO Pharma Investigational Site

Frankfurt am Main, 60590, Germany
LEO Pharma Investigational Site

Haßfurt, 97437, Germany
LEO Pharma Investigational Site

Osnabrück, 49074, Germany
LEO Pharma Investigational Site

Tübingen, 72076, Germany
LEO Pharma Investigational Site

Wuppertal, 42283, Germany
LEO Pharma Investigational Site

Amsterdam, 1105 AZ, Netherlands
LEO Pharma Investigational Site

Groningen, 9713 GZ, Netherlands
LEO Pharma Investigational Site

Gdansk, 80-462, Poland
LEO Pharma Investigational Site

Krakow, 30-033, Poland
LEO Pharma Investigational Site

Krakow, 31-011, Poland
LEO Pharma Investigational Site

Wŏnju, Gangwon-do, 26426, South Korea
LEO Pharma Investigational Site

Ansan-si, Gyeonggi-do, 15355, South Korea
LEO Pharma Investigational Site

Yangsan, Gyeongsangnam-do, 05278, South Korea
LEO Pharma Investigational Site

Daegu, 41944, South Korea
LEO Pharma Investigational Site

Seoul, 03080, South Korea
LEO Pharma Investigational Site

Seoul, 04763, South Korea
LEO Pharma Investigational Site

Seoul, 05030, South Korea
LEO Pharma Investigational Site

Seoul, 05278, South Korea
LEO Pharma Investigational Site

Seoul, 4564, South Korea
LEO Pharma Investigational Site

Badalona, Barcelona, 08916, Spain
LEO Pharma Investigational Site

Salford, Greater Manchester, M6 8HD, United Kingdom
LEO Pharma Investigational Site

Middlesbrough, North Yorkshire, TS4 3BW, United Kingdom
LEO Pharma Investigational Site

London, SE1 7EH, United Kingdom
LEO Pharma Investigational site

Ghent, 9000, Belgium
LEO Pharma Investigational site

Alicante, 03010, Spain
LEO Pharma Investigational site

Barcelona, 08916, Spain
LEO Pharma Investigational site

Granada, 18016, Spain

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS ATOPIC HAND ECZEMA